专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20180073007A9 FUSION PROTEINS FOR THE TREATMENT OF CNS 审中-公开
公开(公告)号：US20180073007A9
公开(公告)日：2018-03-15
申请号：US14535113
申请日：2014-11-06
申请人： ACORDA THERAPEUTICS, INC.
发明人： Elliott A. GRUSKIN , Anthony O. CAGGIANO , Gargi ROY , Jennifer IACI , Michael P. ZIMBER
IPC分类号： C12N9/88 , A61K38/51 , A61K35/30
CPC分类号： C12N9/88 , A61K35/30 , A61K38/00 , A61K38/51 , A61K45/06 , C07K14/005 , C07K19/00 , C07K2319/00 , C07K2319/03 , C07K2319/10 , C12N9/2408 , C12Y302/01035 , C12Y302/01036 , C12Y402/02001 , C12Y402/02004 , C12Y402/02005
摘要： This disclosure relates to compositions capable of use in the treatment of spinal cord injuries and related disorders of the central nervous system (CNS), and in particular, compositions including proteoglycan degrading molecules and compositions capable of blocking and/or over coming the activity of neuronal growth inhibitory molecules, as well as fusion proteins which includes a proteoglycan degrading domain and a domain capable of blocking and or over coming the activity of neuronal growth inhibitory molecules.

2. 发明授权

US09770494B2 Pharmacological vitreolysis 有权
公开(公告)号：US09770494B2
公开(公告)日：2017-09-26
申请号：US14318232
申请日：2014-06-27
申请人： ThromboGenics NV
发明人： Steve Pakola , Marc De Smet
IPC分类号： A61K38/48 , A61K45/06
CPC分类号： A61K38/484 , A61K45/06 , C12Y302/01023 , C12Y302/01035 , C12Y304/21007 , C12Y304/24007 , C12Y402/02004 , C12Y402/02005 , C12Y402/02019 , A61K2300/00
摘要： A method of treating or preventing a disorder, or a complication of a disorder, of an eye of a subject comprising contacting a vitreous and/or aqueous humor with a composition comprising a truncated form of plasmin comprising a catalytic domain of plasmin (TPCD). TPCDs include, but are not limited to, miniplasmin, microplasmin and derivatives and variants thereof. The methods of the invention can be used to reduce the viscosity of the vitreous, liquefy the vitreous, induce posterior vitreous detachment, reduce hemorrhagic blood from the eye, clear or reduce materials toxic to the eye, clear or reduce intraocular foreign substances from the eye, increase diffusion of a composition administered to an eye, reduce extraretinal neovascularization and any combinations thereof. The method can be used in the absence of, or as an adjunct to, vitrectomy.

3. 发明授权

US09186394B2 Pharmacological vitreolysis 有权
公开(公告)号：US09186394B2
公开(公告)日：2015-11-17
申请号：US13827986
申请日：2013-03-14
申请人： ThromboGenics NV
发明人： Steve Pakola , Marc De Smet
IPC分类号： A61K38/48 , A61K38/43 , A61M35/00 , A61K45/06
CPC分类号： A61K38/484 , A61K45/06 , C12Y302/01023 , C12Y302/01035 , C12Y304/21007 , C12Y304/24007 , C12Y402/02004 , C12Y402/02005 , C12Y402/02019 , A61K2300/00
摘要： A method of treating or preventing a disorder, or a complication of a disorder, of an eye of a subject comprising contacting a vitreous and/or aqueous humor with a composition comprising a truncated form of plasmin comprising a catalytic domain of plasmin (TPCD). TPCDs include, but are not limited to, miniplasmin, microplasmin and derivatives and variants thereof. The methods of the invention can be used to reduce the viscosity of the vitreous, liquefy the vitreous, induce posterior vitreous detachment, reduce hemorrhagic blood from the eye, clear or reduce materials toxic to the eye, clear or reduce intraocular foreign substances from the eye, increase diffusion of a composition administered to an eye, reduce extraretinal neovascularization and any combinations thereof. The method can be used in the absence of, or as an adjunct to, vitrectomy.

4. 发明申请

US20110300123A1 PHARMACOLOGICAL VITREOLYSIS 有权
标题翻译：药理学研究
公开(公告)号：US20110300123A1
公开(公告)日：2011-12-08
申请号：US13097985
申请日：2011-04-29
申请人： Steve PAKOLA , Marc DE SMET
发明人： Steve PAKOLA , Marc DE SMET
IPC分类号： A61K38/48 , A61P27/02
CPC分类号： A61K38/484 , A61K45/06 , C12Y302/01023 , C12Y302/01035 , C12Y304/21007 , C12Y304/24007 , C12Y402/02004 , C12Y402/02005 , C12Y402/02019 , A61K2300/00
摘要： A method of treating or preventing a disorder, or a complication of a disorder, of an eye of a subject comprising contacting a vitreous and/or aqueous humor with a composition comprising a truncated form of plasmin comprising a catalytic domain of plasmin (TPCD). TPCDs include, but are not limited to, miniplasmin, microplasmin and derivatives and variants thereof. The methods of the invention can be used to reduce the viscosity of the vitreous, liquefy the vitreous, induce posterior vitreous detachment, reduce hemorrhagic blood from the eye, clear or reduce materials toxic to the eye, clear or reduce intraocular foreign substances from the eye, increase diffusion of a composition administered to an eye, reduce extraretinal neovascularization and any combinations thereof. The method can be used in the absence of, or as an adjunct to, vitrectomy.
摘要翻译：治疗或预防受试者眼睛疾病或病症并发症的方法，包括使玻璃体和/或房水与包含纤维蛋白溶酶的催化结构域（TPCD）的截短形式的纤溶酶的组合物接触。 TPCD包括但不限于微型血小板，微量血浆及其衍生物和变体。本发明的方法可用于降低玻璃体粘度，液化玻璃体，诱导玻璃体后脱离，减少眼睛出血血液，清除或减少眼睛有毒的物质，清除或减少眼内异物增加施用于眼睛的组合物的扩散，减少外耳道新生血管形成及其任何组合。该方法可用于玻璃体切除术的缺失或辅助。

5. 发明申请

US20110250631A1 PROTEOGLYCAN DEGRADING MUTANTS FOR TREATMENT OF CNS 审中-公开
标题翻译：用于治疗CNS的PROTEGLYCAN降级药物
公开(公告)号：US20110250631A1
公开(公告)日：2011-10-13
申请号：US13112985
申请日：2011-05-20
申请人： Elliott A. GRUSKIN , Rohini D'SOUZA , Gargi ROY , Anthony G. Caggiano
发明人： Elliott A. GRUSKIN , Rohini D'SOUZA , Gargi ROY , Anthony G. Caggiano
IPC分类号： C12Q1/02 , C12N9/26 , C12N5/071 , C12N9/24 , C07H21/00 , C12N15/63
CPC分类号： C12N9/88 , A61K35/30 , A61K38/00 , A61K38/51 , A61K45/06 , C07K14/005 , C07K19/00 , C07K2319/00 , C07K2319/03 , C07K2319/10 , C12N9/2408 , C12Y302/01035 , C12Y302/01036 , C12Y402/02001 , C12Y402/02004 , C12Y402/02005
摘要： The present disclosure relates to the preparation and deletion mutants of chondroitinase proteins and their use in methods for promoting the diffusion of therapeutic composition into tissues and their use for neurological functional recovery after central nervous system (“CNS”) injury or disease.
摘要翻译：本公开涉及软骨素酶蛋白的制备和缺失突变体及其在促进治疗组合物扩散到组织中的方法及其在中枢神经系统（“CNS”）损伤或疾病之后神经功能恢复的用途。

6. 发明申请

US20150023942A1 COMPOSITIONS AND METHODS FOR PROMOTING NEURONAL OUTGROWTH 有权
标题翻译：用于促进神经生长的组成和方法
公开(公告)号：US20150023942A1
公开(公告)日：2015-01-22
申请号：US14317106
申请日：2014-06-27
申请人： Acorda Therapeutics, Inc.
发明人： Elliott A. Gruskin , Jennifer F. Iaci , Andrea M. Vecchione , Sara J. Kasperbauer , Gargi Roy
IPC分类号： A61K38/51
CPC分类号： A61K38/51 , C12N9/88 , C12Y402/02005 , C12Y402/02019
摘要： Neural outgrowth in the central nervous system is achieved by administering chondroitinase AC and/or chondroitinase B to degrade chondroitin sulfate proteoglycans that inhibit or contribute to the inhibition of nervous tissue regeneration.
摘要翻译：通过施用软骨素酶AC和/或软骨素酶B来降解抑制或有助于抑制神经组织再生的硫酸软骨素蛋白聚糖来实现中枢神经系统中的神经生长。

7. 发明授权

US08785606B2 Compositions and methods for promoting neuronal outgrowth 有权
标题翻译：促进神经元生长的组成和方法
公开(公告)号：US08785606B2
公开(公告)日：2014-07-22
申请号：US13451968
申请日：2012-04-20
申请人： Elliott A. Gruskin , Jennifer F. Iaci , Andrea M. Vecchione , Sarah J. Kasperbauer , Gargi Roy
发明人： Elliott A. Gruskin , Jennifer F. Iaci , Andrea M. Vecchione , Sarah J. Kasperbauer , Gargi Roy
IPC分类号： A61K38/48 , A61K31/726 , A61K31/737
CPC分类号： A61K38/51 , C12N9/88 , C12Y402/02005 , C12Y402/02019
摘要： Neural outgrowth in the central nervous system is achieved by administering chondroitinase AC and/or chondroitinase B to degrade chondroitin sulfate proteoglycans that inhibit or contribute to the inhibition of nervous tissue regeneration.
摘要翻译：通过施用软骨素酶AC和/或软骨素酶B来降解抑制或有助于抑制神经组织再生的硫酸软骨素蛋白聚糖来实现中枢神经系统中的神经生长。

8. 发明申请

US20130202613A1 PHARMACOLOGICAL VITREOLYSIS 审中-公开
公开(公告)号：US20130202613A1
公开(公告)日：2013-08-08
申请号：US13690427
申请日：2012-11-30
申请人： ThromboGenics NV
发明人： Steve PAKOLA , Marc DE SMET
IPC分类号： A61K38/48 , A61K45/06
CPC分类号： A61K38/484 , A61K45/06 , C12Y302/01023 , C12Y302/01035 , C12Y304/21007 , C12Y304/24007 , C12Y402/02004 , C12Y402/02005 , C12Y402/02019 , A61K2300/00
摘要： A method of treating or preventing a disorder, or a complication of a disorder, of an eye of a subject comprising contacting a vitreous and/or aqueous humor with a composition comprising a truncated form of plasmin comprising a catalytic domain of plasmin (TPCD). TPCDs include, but are not limited to, miniplasmin, microplasmin and derivatives and variants thereof. The methods of the invention can be used to reduce the viscosity of the vitreous, liquefy the vitreous, induce posterior vitreous detachment, reduce hemorrhagic blood from the eye, clear or reduce materials toxic to the eye, clear or reduce intraocular foreign substances from the eye, increase diffusion of a composition administered to an eye, reduce extraretinal neovascularization and any combinations thereof. The method can be used in the absence of, or as an adjunct to, vitrectomy.

9. 发明授权

US07867489B2 Pharmacological vitreolysis 有权
标题翻译：药理性玻璃体解
公开(公告)号：US07867489B2
公开(公告)日：2011-01-11
申请号：US12156911
申请日：2008-06-05
申请人： Steve Pakola , Marc De Smet
发明人： Steve Pakola , Marc De Smet
IPC分类号： A61K38/48 , A61K38/43 , A61M35/00
CPC分类号： A61K38/484 , A61K45/06 , C12Y302/01023 , C12Y302/01035 , C12Y304/21007 , C12Y304/24007 , C12Y402/02004 , C12Y402/02005 , C12Y402/02019 , A61K2300/00
摘要： A method of treating or preventing a disorder, or a complication of a disorder, of an eye of a subject comprising contacting a vitreous and/or aqueous humor with a composition comprising a truncated form of plasmin comprising a catalytic domain of plasmin (TPCD). TPCDs include, but are not limited to, miniplasmin, microplasmin and derivatives and variants thereof. The methods of the invention can be used to reduce the viscosity of the vitreous, liquefy the vitreous, induce posterior vitreous detachment, reduce hemorrhagic blood from the eye, clear or reduce materials toxic to the eye, clear or reduce intraocular foreign substances from the eye, increase diffusion of a composition administered to an eye, reduce extraretinal neovascularization and any combinations thereof. The method can be used in the absence of, or as an adjunct to, vitrectomy.
摘要翻译：治疗或预防受试者眼睛疾病或病症并发症的方法，包括使玻璃体和/或房水与包含纤维蛋白溶酶的催化结构域（TPCD）的截短形式的纤溶酶的组合物接触。 TPCD包括但不限于微型血小板，微量血浆及其衍生物和变体。本发明的方法可用于降低玻璃体粘度，液化玻璃体，诱导玻璃体后脱离，减少眼睛出血血液，清除或减少眼睛有毒的物质，清除或减少眼内异物增加施用于眼睛的组合物的扩散，减少外耳道新生血管形成及其任何组合。该方法可用于玻璃体切除术的缺失或辅助。

10. 发明申请

US20090028829A1 Fusion proteins for the treatment of CNS 有权
标题翻译：用于治疗CNS的融合蛋白
公开(公告)号：US20090028829A1
公开(公告)日：2009-01-29
申请号：US10848564
申请日：2004-05-17
申请人： Elliott A. Gruskin , Anthony O. Caggiano , Gargi Roy , Jennifer Iaci , Michael P. Zimber
发明人： Elliott A. Gruskin , Anthony O. Caggiano , Gargi Roy , Jennifer Iaci , Michael P. Zimber
IPC分类号： A61K35/12 , A61K38/47 , A61K38/02 , A61P25/00
CPC分类号： C12N9/88 , A61K35/30 , A61K38/00 , A61K38/51 , A61K45/06 , C07K14/005 , C07K19/00 , C07K2319/00 , C07K2319/03 , C07K2319/10 , C12N9/2408 , C12Y302/01035 , C12Y302/01036 , C12Y402/02001 , C12Y402/02004 , C12Y402/02005
摘要： This disclosure relates to compositions capable of use in the treatment of spinal cord injuries and related disorders of the central nervous system (CNS), and in particular, compositions including proteoglycan degrading molecules and compositions capable of blocking and/or over coming the activity of neuronal growth inhibitory molecules, as well as fusion proteins which includes a proteoglycan degrading domain and a domain capable of blocking and or over coming the activity of neuronal growth inhibitory molecules.
摘要翻译：本公开涉及能够用于治疗脊髓损伤和中枢神经系统（CNS）的相关病症的组合物，特别是包括蛋白多糖降解分子和能够阻断和/或超过神经元活性的组合物的组合物生长抑制分子，以及融合蛋白，其包括蛋白聚糖降解结构域和能够阻断和或超过神经元生长抑制分子活性的结构域。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式